NCT05622682Completed
Vaccine Immune Recovery After Leukemia
A Prospective Cohort Study to Define Infectious Burden, the Seroprevalence of Vaccine Preventable Pathogens and Immune Recovery in the First Year Following Completion of Therapy in Patients With Acute Lymphoblastic Leukemia (ALL)
Source: ClinicalTrials.gov · Last updated 26 Jan 2026
Brief summary (registry, in English)
This observational study aims to assess recovery of the immune system and immunity to vaccine-preventable diseases in children, adolescents, and young adults who recently completed treatment for acute lymphoblastic leukemia (ALL). Several children's hospitals in the United States are participating in the study, which will enroll up to 100 pediatric participants. The study is intended to determine the rate of infection after leukemia treatment and to inform future studies and recommendations about whether children and adolescents who have leukemia should receive additional vaccine doses or boosters after treatment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 89 (actual)
- First submitted
- 9 Nov 2022
- Start date
- 28 Sept 2022
- Primary completion date
- 31 Oct 2025
- Lead sponsor
- Children's Hospital of Philadelphia
- NCT number
- NCT05622682
What you commit to
- Study type: Observational
- Participants enrolled: 89
- From 28 Sept 2022 to the primary completion date, 31 Oct 2025
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Evidence of disease relapse
- History of primary immunodeficiency (except related to Down Syndrome)
- History of a stem cell transplant or cellular immunotherapy
- History of prior malignancy or condition requiring chemotherapy other than for current ALL diagnosis
Other
- Diagnosis of infant ALL
Who the study is looking for
- Children, adolescents, and young adults diagnosed with B or T ALL at age 12 months or older
- Completed ALL chemotherapy within the past three months or will complete ALL chemotherapy in the upcoming three months
- Three years of age or older at time of enrollment
Age in the registry: 3 years to 31 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ann & Robert H. Lurie Children's Hospital of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
| Helen DeVos Children's Hospital Coordinator of this site? Confirm its status | Grand Rapids | United States | Unknown status |
| Monroe Carell Jr. Children's Hospital at Vanderbilt Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
| Children's Hospital of Philadelphia Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| CHRISTUS Children's (Affiliate of Baylor College of Medicine) Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
| Seattle Children's Hospital Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.